These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 455324)

  • 41. Value of echocardiography and electrocardiography as screening tools prior to Doxorubicin administration.
    Ratterree W; Gieger T; Pariaut R; Saelinger C; Strickland K
    J Am Anim Hosp Assoc; 2012; 48(2):89-96. PubMed ID: 22267175
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adriamycin cardiomyopathy--risk factors.
    Minow RA; Benjamin RS; Lee ET; Gottlieb JA
    Cancer; 1977 Apr; 39(4):1397-402. PubMed ID: 856438
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serial studies of cardiac function in patients receiving adriamycin.
    Henderson IC; Sloss LJ; Jaffe N; Blum RH; Frei E
    Cancer Treat Rep; 1978 Jun; 62(6):923-9. PubMed ID: 667869
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity.
    Weiss AJ; Manthel RW
    Cancer; 1977 Nov; 40(5):2046-52. PubMed ID: 336177
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Assessment of adriamycin cardiotoxicity in children by systolic time intervals.
    Ulmer HE; Ludwig R; Geiger H
    Eur J Pediatr; 1979 Apr; 131(1):21-31. PubMed ID: 436854
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy.
    Torti FM; Bristow MR; Howes AE; Aston D; Stockdale FE; Carter SK; Kohler M; Brown BW; Billingham ME
    Ann Intern Med; 1983 Dec; 99(6):745-9. PubMed ID: 6651020
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevention of adriamycin-induced cardiotoxicity by prenylamine: a pilot double blind study.
    Milei J; Marantz A; Alé J; Vazquez A; Buceta JE
    Cancer Drug Deliv; 1987; 4(2):129-36. PubMed ID: 3427552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Doxorubicin-induced cardiomyopathy.
    Dunn J
    J Pediatr Oncol Nurs; 1994 Oct; 11(4):152-60. PubMed ID: 7946145
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Characterization and comparison of the clinical and morphological changes in adriamycin cardiomyopathy].
    Bühner R; Henrichs J; Gottschalk R
    Onkologie; 1979 Feb; 2(1):24-7. PubMed ID: 392366
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Electrocardiographic changes following adriamycin treatment.
    Dindogru A; Barcos M; Henderson ES; Wallace HJ
    Med Pediatr Oncol; 1978; 5(1):65-71. PubMed ID: 745592
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The meaning of bites on the vectorcardiogram: study in adriamycin cardiomyopathy.
    Vitolo E; Madoi S; Colli AM; Roveda M; La Rovere MT; Obbiassi M; Labianca R
    J Electrocardiol; 1982; 15(3):265-70. PubMed ID: 7119636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine.
    Myers C; Bonow R; Palmeri S; Jenkins J; Corden B; Locker G; Doroshow J; Epstein S
    Semin Oncol; 1983 Mar; 10(1 Suppl 1):53-5. PubMed ID: 6340204
    [No Abstract]   [Full Text] [Related]  

  • 53. Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature.
    Diehl LF; Banks A; Carter W; Klein MA; Muss HB; Weiss RB
    Cancer Chemother Pharmacol; 1988; 21(4):347-50. PubMed ID: 3286024
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacology of adriamycin: the message to the clinician.
    Cummings J; Smyth JF
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):579-82. PubMed ID: 3289943
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy.
    Cardinale D; Colombo A; Cipolla CM
    Curr Treat Options Cardiovasc Med; 2008 Dec; 10(6):486-95. PubMed ID: 19026179
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cardiomyopathies in children.
    Hong YM
    Korean J Pediatr; 2013 Feb; 56(2):52-9. PubMed ID: 23482511
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Cardiologic monitoring of patients under adriamycin therapy].
    Höfling B; Bolte HD
    Onkologie; 1981 Jun; 4(3):174-8. PubMed ID: 7022294
    [No Abstract]   [Full Text] [Related]  

  • 58. Evaluation of cardiac function during adriamycin therapy.
    Burg JR; Moseley HS; Lindell TD; Kremkau EL; Fletcher WS
    J Surg Oncol; 1974; 6(6):519-29. PubMed ID: 4453130
    [No Abstract]   [Full Text] [Related]  

  • 59. Cardiomyopathies in Children and Systemic Disorders When Is It Useful to Look beyond the Heart?
    Lodato V; Parlapiano G; Calì F; Silvetti MS; Adorisio R; Armando M; El Hachem M; Romanzo A; Dionisi-Vici C; Digilio MC; Novelli A; Drago F; Raponi M; Baban A
    J Cardiovasc Dev Dis; 2022 Jan; 9(2):. PubMed ID: 35200700
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 2017 CMP Honoree: Professor Shirley Lindenbaum.
    Gaines AD
    Cult Med Psychiatry; 2017 Dec; 41(4):471-472. PubMed ID: 29030747
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.